Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

Rhea-AI Summary

Nautilus Biotechnology (NASDAQ: NAUT) reported its Q2 2025 financial results, highlighting significant progress in its single-molecule proteome analysis platform development. The company published its first scientific manuscript demonstrating the Iterative Mapping method for measuring proteoforms with unprecedented resolution. Additionally, Nautilus secured two new collaborations with research institutes focusing on Tau proteoform studies in Alzheimer's disease research.

Financial results showed operating expenses of $17.1 million, an 18% decrease from $20.8 million in Q2 2024. The company reported a net loss of $15.0 million, improved from $18.0 million year-over-year. Cash, cash equivalents, and investments stood at $179.5 million as of June 30, 2025.

Positive

• Successful publication of first scientific manuscript validating the Iterative Mapping method
• Secured two new research collaborations for Tau proteoform studies
• 18% reduction in operating expenses year-over-year
• Strong cash position of $179.5 million
• Improved net loss position compared to previous year

Negative

• Continued net loss of $15.0 million in Q2 2025

Insights

Biotechnology Analyst

Nautilus reports reduced Q2 losses while advancing its novel proteomics platform through scientific validation and research collaborations.

Nautilus Biotechnology's Q2 2025 financial results showcase a company making scientific progress while carefully managing resources. The company reported $17.1 million in operating expenses, representing a 18% decrease year-over-year, while net losses decreased from $18.0 million to $15.0 million. Their cash position remains strong at $179.5 million, providing a substantial runway for continued platform development.

Beyond the financials, the quarter marked significant technological milestones. The publication of the first scientific manuscript featuring data generated on their platform represents a crucial validation step for their Iterative Mapping method, which they claim can measure proteoforms at unprecedented resolution and breadth. This addresses a fundamental challenge in proteomics - the ability to detect and analyze protein variants with high precision.

The two new collaborations with research institutes focusing on Tau proteoform analysis in Alzheimer's disease contexts are particularly noteworthy. Tau proteins and their post-translational modifications play critical roles in neurodegenerative diseases, and improved analytical capabilities could accelerate biomarker discovery. These partnerships strategically position Nautilus in the high-value neurodegenerative disease research space while providing external validation of their technology's capabilities.

The reduction in operating expenses while maintaining research momentum suggests improved operational efficiency. The focus on cost optimization without apparently sacrificing development pace indicates prudent management in an environment where biotech investors increasingly demand capital efficiency alongside innovation.

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025.

“In Q2, we achieved major milestones that underscore the continued advancement of our platform,” said Sujal Patel, CEO of Nautilus Biotechnology. “Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and collaborators. In it, we introduce and validate application of our Iterative Mapping method showing that it can measure proteoforms at a resolution and breadth never before possible.

“We have also signed two collaborations with major research institutes to utilize the Nautilus platform and Tau proteoform assay. Through studies of co-incident post-translational modifications on Tau across brain regions in human tissue and across models of Alzheimer's disease progression we aim to enable researchers to make fundamental advances in understanding disease-relevant biology. Together, these achievements represent both the demonstration and external recognition of the exceptional performance of our platform and mark a critical step toward enabling researchers to uncover proteomic insights that we believe will shape the future of biomarker and therapeutic discovery.”

Second Quarter 2025 Financial Results

Operating expenses were $17.1 million for the second quarter of 2025, a 18% decrease compared to $20.8 million for the corresponding prior year period. The decrease in operating expense is attributable to continued focus on cost optimization, variability in the timing of research and development activities, and decreased salaries, related benefits, stock-based compensation, and professional services expenses.

Net loss was $15.0 million for the second quarter of 2025, as compared to the net loss of $18.0 million for the corresponding prior year period.

Cash, cash equivalents, and investments were $179.5 million as of June 30, 2025.

Webcast and Conference Call Information

Nautilus will host a conference call to discuss the second quarter 2025 financial results, business developments and outlook before market open on Thursday, July 31, 2025, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding operating expenses and cash runway; expectations with respect to any revenue timing or projections; expectations with respect to the development required for and the timing of the launch of Nautilus’ product platform and full commercial availability; the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome or proteoform access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery; expectations regarding platform specifications required by potential customers and partners and the timeline for adoption of Nautilus’ platform by researchers; and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended June 30, 2025 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information

Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

(in thousands)	June 30, 2025				December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	34,457			$	27,646
Short-term investments		113,416				102,247
Prepaid expenses and other current assets		2,852				2,933
Total current assets		150,725				132,826
Property and equipment, net		3,728				4,076
Operating lease right-of-use assets		25,920				28,256
Long-term investments		31,636				76,405
Other long-term assets		1,180				1,180
Total assets	$	213,189			$	242,743
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	974			$	987
Accrued expenses and other liabilities		2,938				2,548
Current portion of operating lease liabilities		4,225				4,097
Total current liabilities		8,137				7,632
Operating lease liabilities, net of current portion		23,958				26,381
Total liabilities		32,095				34,013
Stockholders' equity:
Preferred stock		—				—
Common stock		13				13
Additional paid-in capital		485,669				481,679
Accumulated other comprehensive income		77				57
Accumulated deficit		(304,665	)			(273,019	)
Total stockholders’ equity		181,094				208,730
Total liabilities and stockholders' equity	$	213,189			$	242,743

	Three Months Ended June 30,								Six Months Ended June 30,
(in thousands, except share and per share data)		2025				2024				2025				2024
Operating expenses
Research and development	$	10,394			$	12,436			$	21,930			$	25,366
General and administrative		6,703				8,353				14,011				17,030
Total operating expenses		17,097				20,789				35,941				42,396
Other income (expense):
Interest income		2,080				2,798				4,311				5,675
Other expense		(16	)			(19	)			(16	)			(19	)
Total other income	$	2,064			$	2,779			$	4,295			$	5,656
Net loss	$	(15,033	)		$	(18,010	)		$	(31,646	)		$	(36,740	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.12	)		$	(0.14	)		$	(0.25	)		$	(0.29	)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted		126,204,632				125,317,650				126,174,603				125,226,552

	Six Months Ended June 30,
(in thousands)		2025				2024
Cash flows from operating activities
Net loss	$	(31,646	)		$	(36,740	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense		3,877				6,393
Amortization of operating lease right-of-use assets		2,336				2,160
Depreciation		922				1,028
Amortization (accretion) of premium (discount) on securities, net		(980	)			(1,453	)
Changes in operating assets and liabilities:
Prepaid expenses and other assets		160				(71	)
Accounts payable		(51	)			(308	)
Accrued expenses and other liabilities		390				(706	)
Operating lease liabilities		(2,295	)			(2,026	)
Net cash used in operating activities		(27,287	)			(31,723	)
Cash flows from investing activities
Proceeds from maturities of securities		45,878				53,500
Purchases of securities		(11,278	)			(15,694	)
Purchases of property and equipment		(615	)			(1,159	)
Net cash provided by investing activities		33,985				36,647
Cash flows from financing activities
Proceeds from exercise of stock options		26				275
Proceeds from issuance of common stock under employee stock purchase plan		87				289
Net cash provided by financing activities		113				564
Net increase in cash, cash equivalents and restricted cash		6,811				5,488
Cash, cash equivalents and restricted cash at beginning of period		28,648				20,399
Cash, cash equivalents and restricted cash at end of period	$	35,459			$	25,887

FAQ

What were Nautilus Biotechnology's (NAUT) key financial results for Q2 2025?

Nautilus reported operating expenses of $17.1 million, a net loss of $15.0 million, and maintained a strong cash position of $179.5 million as of June 30, 2025.

What major milestones did Nautilus Biotechnology achieve in Q2 2025?

Nautilus published its first scientific manuscript demonstrating the Iterative Mapping method and secured two new collaborations with research institutes for Tau proteoform studies in Alzheimer's disease research.

How did Nautilus Biotechnology's Q2 2025 operating expenses compare to the previous year?

Operating expenses decreased by 18% to $17.1 million, compared to $20.8 million in Q2 2024, due to cost optimization efforts and reduced expenses in various areas.

What is the current cash position of Nautilus Biotechnology (NAUT)?

As of June 30, 2025, Nautilus maintained $179.5 million in cash, cash equivalents, and investments.

What new research collaborations did Nautilus Biotechnology announce in Q2 2025?

Nautilus announced two collaborations with major research institutes to utilize their platform and Tau proteoform assay for studying Alzheimer's disease progression across brain regions.